In a murine model of prostate cancer, administration of a CXCR2 antagonist or infusion of bone marrow-derived CXCR2 KO macrophages led to a reduction in tumor growth and a reprogramming of TAMs to a pro-inflammatory, M1 phenotype [14]. Here, CXCR2 is linked to neoplasm.